The Latest Breaking News from AstraZeneca

The researchers cautioned that the study found only associations with adverse health effects and it does not prove that these issues are caused by the vaccines.

Loss of muscle mass also flagged, as UK drugmaker works with China’s Eccogene on obesity and type 2 diabetes pill

AstraZeneca's quarterly results were "thoroughly underwhelming," an analyst said Thursday as he downgraded AZN stock to a sell rating.

London’s long-awaited run of dealmaking action continued today when Tesco unveiled the sale of its banking operations to Barclays.

Other lives: Specialist in cell biology who helped with the development of a Covid-19 vaccine and treatments for cystic fibrosis

Gracell Biotechnologies acquisition marks China’s growing importance to the Anglo-Swedish drugmaker

Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business

Scientists have offered a new explanation for why COVID-19 vaccines that contained adenoviruses carried a rare-but-serious risk of blood clotting.

Absci, a drug and target discovery company, has been harnessing the power of deep learning AI to develop new and existing disease treatments.

The team discovered that people who previously received AstraZeneca or Sinopharm COVID-19 vaccines had a "non-inferior" immune response when given a half dose of a Pfizer COVID-19 booster vaccine, comparable to those who received a full dose.

Several pharmaceutical companies are racing to develop obesity drugs and tap into a surge in consumer demand for the extremely profitable drugs. Sales of Eli Lilly’s (LLY ) diabetes drug Mounjaro, just approved by the U.S. Food and Drug Administration (FDA) for obesity in the U.S., hit $1.41 billion in...